Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker

Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance

(2010) Junko Kikuchi et al.   CANCER

Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers

(2010) Masanori Yoshimatsu et al.   INTERNATIONAL JOURNAL OF CANCER

Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers

(2010) Shinya Hayami et al.   INTERNATIONAL JOURNAL OF CANCER

Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors

(2010) Qiong Zhao et al.   LUNG CANCER

Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway

(2010) Shinya Hayami et al.   Molecular Cancer

UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer

(2009) M Unoki et al.   BRITISH JOURNAL OF CANCER

Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis

(2009) Ø Fluge et al.   BRITISH JOURNAL OF CANCER

Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer

(2009) Motoki Miyazawa et al.   CANCER SCIENCE

Aurora Kinases as Anticancer Drug Targets

(2008) O. Gautschi et al.   CLINICAL CANCER RESEARCH